Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as did existing investors Deerfield Management, Boyu Capital and WuXi AppTec Corporate Ventures, plus existing non-institutional investors.

By the end of 2019, FOG plans to begin clinical testing of its first product, a beta-catenin (CTNNB1) inhibitor, to treat cancers activated by the Wnt pathway...